These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 18687386

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
    Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA.
    J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
    [Abstract] [Full Text] [Related]

  • 6. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
    Conti MM, Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Dell'isola R, Katzman AC, Bishop C.
    Neuropharmacology; 2014 Feb; 77():1-8. PubMed ID: 24067924
    [Abstract] [Full Text] [Related]

  • 7. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
    Dupre KB, Eskow KL, Steiniger A, Klioueva A, Negron GE, Lormand L, Park JY, Bishop C.
    Psychopharmacology (Berl); 2008 Jul; 199(1):99-108. PubMed ID: 18545986
    [Abstract] [Full Text] [Related]

  • 8. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
    Thornton E, Hassall MM, Corrigan F, Vink R.
    Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
    [Abstract] [Full Text] [Related]

  • 9. Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
    Barnum CJ, Bhide N, Lindenbach D, Surrena MA, Goldenberg AA, Tignor S, Klioueva A, Walters H, Bishop C.
    Pharmacol Biochem Behav; 2012 Jan; 100(3):607-15. PubMed ID: 21978941
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease.
    Holden H, Venkatesh S, Budrow C, Nezaria S, Coyle M, Centner A, Lipari N, McManus G, Bishop C.
    Physiol Behav; 2024 Jul 01; 281():114563. PubMed ID: 38723388
    [Abstract] [Full Text] [Related]

  • 16. Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
    Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Bishop C.
    Behav Brain Res; 2014 Aug 15; 270():75-85. PubMed ID: 24837745
    [Abstract] [Full Text] [Related]

  • 17. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Tsunekawa H, Takahata K, Okano M, Ishikawa T, Satoyoshi H, Nishimura T, Hoshino N, Muraoka S.
    Behav Brain Res; 2018 Jul 16; 347():350-359. PubMed ID: 29526790
    [Abstract] [Full Text] [Related]

  • 18. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E, Lisci C, Stancampiano R, Fidalgo C, Collu M, Devoto P, Carta M.
    Neurobiol Dis; 2013 Dec 16; 60():108-14. PubMed ID: 24004632
    [Abstract] [Full Text] [Related]

  • 19. Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT1A/1B receptor agonist and A2A receptor antagonist.
    Pinna A, Costa G, Serra M, Contu L, Morelli M.
    Neuropharmacology; 2021 Sep 15; 196():108693. PubMed ID: 34229013
    [Abstract] [Full Text] [Related]

  • 20. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
    Sellnow RC, Steece-Collier K, Altwal F, Sandoval IM, Kordower JH, Collier TJ, Sortwell CE, West AR, Manfredsson FP.
    J Neurosci; 2020 Apr 29; 40(18):3675-3691. PubMed ID: 32238479
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.